An updated review on pathogenic coronaviruses (CoVs) amid the emergence of SARS-CoV-2 variants : A look into the repercussions and possible solutions
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved..
SARS-CoV-2, responsible for COVID-19, shares 79% and 50% of its identity with SARS-CoV-1 and MERS-CoV, respectively. It uses the same main cell attachment and entry receptor as SARS-CoV-1, which is the ACE-2 receptor. However, key residues in the receptor-binding domain of its S-protein seem to give it a stronger affinity for the receptor and a better ability to hide from the host immune system. Like SARS-CoV-1 and MERS-CoV, cytokine storms in critically ill COVID-19 patients cause ARDS, neurological pathology, multiorgan failure, and increased death. Though many issues remain, the global research effort and lessons from SARS-CoV-1 and MERS-CoV are hopeful. The emergence of novel SARS-CoV-2 variants and subvariants raised serious concerns among the scientific community amid the emergence of other viral diseases like monkeypox and Marburg virus, which are major concerns for healthcare settings worldwide. Hence, an updated review on the comparative analysis of various coronaviruses (CoVs) has been developed, which highlights the evolution of CoVs and their repercussions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Journal of infection and public health - 16(2023), 11 vom: 01. Nov., Seite 1870-1883 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rabaan, Ali A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 01.11.2023 Date Revised 01.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jiph.2023.09.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363321772 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363321772 | ||
| 003 | DE-627 | ||
| 005 | 20231226093111.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jiph.2023.09.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1211.xml |
| 035 | |a (DE-627)NLM363321772 | ||
| 035 | |a (NLM)37839310 | ||
| 035 | |a (PII)S1876-0341(23)00309-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rabaan, Ali A |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An updated review on pathogenic coronaviruses (CoVs) amid the emergence of SARS-CoV-2 variants |b A look into the repercussions and possible solutions |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.11.2023 | ||
| 500 | |a Date Revised 01.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a SARS-CoV-2, responsible for COVID-19, shares 79% and 50% of its identity with SARS-CoV-1 and MERS-CoV, respectively. It uses the same main cell attachment and entry receptor as SARS-CoV-1, which is the ACE-2 receptor. However, key residues in the receptor-binding domain of its S-protein seem to give it a stronger affinity for the receptor and a better ability to hide from the host immune system. Like SARS-CoV-1 and MERS-CoV, cytokine storms in critically ill COVID-19 patients cause ARDS, neurological pathology, multiorgan failure, and increased death. Though many issues remain, the global research effort and lessons from SARS-CoV-1 and MERS-CoV are hopeful. The emergence of novel SARS-CoV-2 variants and subvariants raised serious concerns among the scientific community amid the emergence of other viral diseases like monkeypox and Marburg virus, which are major concerns for healthcare settings worldwide. Hence, an updated review on the comparative analysis of various coronaviruses (CoVs) has been developed, which highlights the evolution of CoVs and their repercussions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Coronaviruses (CoVs) | |
| 650 | 4 | |a Immune response | |
| 650 | 4 | |a Immunopathogenesis | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Variants | |
| 650 | 4 | |a Viral evolution | |
| 700 | 1 | |a Alenazy, Maha Fahad |e verfasserin |4 aut | |
| 700 | 1 | |a Alshehri, Ahmad A |e verfasserin |4 aut | |
| 700 | 1 | |a Alshahrani, Mohammed Abdulrahman |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Subaie, Maha F |e verfasserin |4 aut | |
| 700 | 1 | |a Alrasheed, Hayam A |e verfasserin |4 aut | |
| 700 | 1 | |a Al Kaabi, Nawal A |e verfasserin |4 aut | |
| 700 | 1 | |a Thakur, Nanamika |e verfasserin |4 aut | |
| 700 | 1 | |a Bouafia, Nabiha A |e verfasserin |4 aut | |
| 700 | 1 | |a Alissa, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Alsulaiman, Abdulrahman M |e verfasserin |4 aut | |
| 700 | 1 | |a AlBaadani, Abeer M |e verfasserin |4 aut | |
| 700 | 1 | |a Alhani, Hatem M |e verfasserin |4 aut | |
| 700 | 1 | |a Alhaddad, Ali H |e verfasserin |4 aut | |
| 700 | 1 | |a Alfouzan, Wadha A |e verfasserin |4 aut | |
| 700 | 1 | |a Ali, Batool Mohammed Abu |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Abdulali, Khadija H |e verfasserin |4 aut | |
| 700 | 1 | |a Khamis, Faryal |e verfasserin |4 aut | |
| 700 | 1 | |a Bayahya, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Al Fares, Mona A |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Manish |e verfasserin |4 aut | |
| 700 | 1 | |a Dhawan, Manish |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of infection and public health |d 2008 |g 16(2023), 11 vom: 01. Nov., Seite 1870-1883 |w (DE-627)NLM200240730 |x 1876-035X |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2023 |g number:11 |g day:01 |g month:11 |g pages:1870-1883 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jiph.2023.09.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2023 |e 11 |b 01 |c 11 |h 1870-1883 | ||